LinkedIn introduce InMaps, mapa de tu red profesional LinkedIn, la red social para los contactos profesionales, ha dado a conocer InMaps, una herramienta que visualiza toda tu red social en un mapa con código de color por asociaciones. Este concepto te permite ver los principales contactos de tu red, así como encontrar posibles áreas de conexión. Solo toma un minuto para que se genere tu propio mapa, aunque también depende del número de contactos que tengas en LinkedIn, yo tengo muy pocos en comparación con amigos en Facebook y contactos en Twitter, debido a que prefiero mantener mi LinkedIn un poco más cerrado por cuestiones de practicidad, así que el resultado fue bastante simple. Varias afiliaciones cuentan con el código de color y entre más grande es el punto, más fuerte la conexión que tiene esa persona en una red en particular. Ve a estos puntos más grandes como los centros, como una especie de conmutador central de información. Lo más interesante y que tal vez no te esperes es que el mapa te muestra áreas de oportunidad.
Survey: Average Health-Insurance Deductible is Now $1,200 - Health Blog By Katherine Hobson Close your eyes and take yourself back to 2005 for a minute: George W. Bush had his second inauguration, “Star Wars: Episode III–Revenge of the Sith” was burning up the box office and health-insurance deductibles were only about $770. But in 2010, the average deductible for PPOs, the most common employer-provider health plan, hit a whopping $1,200, according to a Mercer survey of 2,836 employers with 10 or more employees. The survey also found that total health benefit costs rose 6.9% this year, up from 5.5% in 2009. An earlier study by Mercer found that employers anticipate they will spend about 5.9% more per employee on health care in 2011, after shifting some costs to workers and making other changes. Other trends noted by Mercer: The biggest employers (20,000-plus employees) are boosting enrollment in high-deductible plans linked to health savings accounts more quickly than medium or small businesses. Image: iStockphoto
The Lean Thinker ¿Qué pueden hacer LinkedIn y sus 100 millones de usuarios por tu empresa? Hace poco la red social profesional LinkedIn alcanzó la nada despreciable cifra de 100 millones de usuarios y lo hizo de una forma discreta, sin esa ansiedad mediática con la que se sigue el progresivo acercamiento de su “rival” Facebook a la mágica cifra de los 700 millones de adeptos. Además, el hecho de que el 56% de los usuarios de LinkedIn sean de fuera de los Estados Unidos atestigua el carácter global de su comunidad. En los últimos meses ambas redes sociales han incluido de manera constante una serie de modificaciones importantes. Mientras Facebook buscaba convertirse en un espacio más amigable para usuarios profesionales y corporativos, LinkedIn apostaba por crear un entorno más social para su plataforma, integrando otros canales como Twitter y blogs, incluyendo la posibilidad de seguir a ciertos usuarios al margen de que formen de tu red de contactos o fomentando el uso de grupos (algunos con más de 100.000 miembros) como espacios de debate y para compartir información.
AVEO's RON antibody shows anti-tumor activity in human cancer xenografts AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced preclinical data from AVEO's anti-RON antibody program which demonstrated the successful identification of antibodies with potent anti-tumor activity that demonstrated inhibition of the function of both wild type RON and the RONΔ160 variant, as well as a potential biomarker to identify tumors likely to respond to treatment with the anti-RON antibody. These data were presented yesterday in a late-breaker plenary presentation during the 22nd Annual Symposium of the European Organization for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research (EORTC-NCI-AACR) in Berlin, Germany. The lead antibodies from this program have been humanized for planned therapeutic development. RON (Recepteur d'Origine Nanatais, or MST1R) receptor tyrosine kinase is a member of the c-Met RTK family.
Learning about Lean Amgen receives approval for denosumab (Xgeva) in SRE for cancer At the NY Chemotherapy Foundation Symposium last week, several oncologists I spoke to said that a high price would be a significant barrier to use, so it would be reserved for those who do not respond or tolerate Zometa, or have poor renal function. Urologists would probably be more interested in Xgeva, since Zometa is an infusion product and they tend to refer patients to the oncologist for this. Xgeva, as a subcutaneous therapy, would therefore potentially be a more convenient option for urologists who have patients that progress to symptomatic metastatic prostate cancer. The other interesting thing I noticed from the data presented on Dmab at the NY Chemotherapy Meeting, was that while time to SRE was significantly improved with Xgeva compared to Zometa, there was no difference in survival between either therapy, as measured by both progression-free survival (PFS) and overall survival (OS). Another interesting item was data on a new PARP inhibitor, MK-4827, from Merck.
Lean Is Good 20 Things I Learned About Browsers and the Web AvailAgility I-SPY 2 study speeds up treatment for breast cancer A clinical trial that aims to speed up the study of new treatments for certain subtypes of breast cancer now has a designated study site at the Diane O'Connor Thompson Breast Center at the University of Colorado Hospital. This study, called I-SPY 2, (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis 2) will evaluate which medical treatments are most effective for different types of tumors. So-called "personalized medicine" in cancer is gaining ground as new drugs are developed that target known gene mutations. In the past, "it could take hundreds of thousands of dollars and several years to study a single drug", says Anthony Elias, MD, breast cancer program director and associate director for clinical research at the University of Colorado Cancer Center (UCCC). "HER2 and triple negative breast cancers are usually bad actors, but some of the ER positive breast cancers can also be aggressive," Elias says.
Lean Manufacturing Blog, Kaizen Articles and Advice | Gemba Panta Rei Doctor Suing Patients Over Negative Yelp Reviews Dr. Jay Pensler, a plastic surgeon in Chicago, isn’t happy with services such as Yelp. The doctor, unhappy about negative reviews his former patients posted on Yelp and Citysearch, is suing at least three of them for defamation. In court papers, Pensler, who calls himself a “well respected plastic surgeon,” says the women have “embarked on a malicious campaign to undermine and destroy” his personal reputation. On the review sites, many women claiming to be former patients offered descriptive and disturbing accounts of their encounters with the Chicago surgeon. “The end result after my surgery was that I had Frankenstein breasts with the nipples placed too high,” one woman writing under the name “rinasa” posted on Citysearch in June 2009. On Yelp, another woman said her breasts looked like something out of a horror film. One of the women’s lawyers feels that the suits will be dismissed, but not until after each woman racks up thousands’ of dollars in legal fees. What do you think?